[go: up one dir, main page]

ATE525375T1 - Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1 - Google Patents

Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1

Info

Publication number
ATE525375T1
ATE525375T1 AT08726699T AT08726699T ATE525375T1 AT E525375 T1 ATE525375 T1 AT E525375T1 AT 08726699 T AT08726699 T AT 08726699T AT 08726699 T AT08726699 T AT 08726699T AT E525375 T1 ATE525375 T1 AT E525375T1
Authority
AT
Austria
Prior art keywords
inhibitors
protein kinase
dependent protein
janus kinases
phosphoinositide dependent
Prior art date
Application number
AT08726699T
Other languages
English (en)
Inventor
Ekaterina Kozina
Christopher Dinsmore
Tony Siu
Jonathan Young
Alan Northrup
Michael Altman
Kevin Keenan
David Guerin
Joon Jung
Rachel Maccoss
Solomon Kattar
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE525375T1 publication Critical patent/ATE525375T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT08726699T 2007-03-13 2008-03-10 Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1 ATE525375T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90675307P 2007-03-13 2007-03-13
PCT/US2008/003206 WO2008112217A1 (en) 2007-03-13 2008-03-10 Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1

Publications (1)

Publication Number Publication Date
ATE525375T1 true ATE525375T1 (de) 2011-10-15

Family

ID=39759836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08726699T ATE525375T1 (de) 2007-03-13 2008-03-10 Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1

Country Status (7)

Country Link
US (1) US8329722B2 (de)
EP (1) EP2134346B1 (de)
JP (1) JP2010521459A (de)
AT (1) ATE525375T1 (de)
AU (1) AU2008226844A1 (de)
CA (1) CA2679694A1 (de)
WO (1) WO2008112217A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200612B1 (de) * 2007-09-11 2012-08-08 Schering Corporation Januskinase-hemmer
CA2707491A1 (en) * 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
AU2008340421B2 (en) * 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
WO2010144486A1 (en) * 2009-06-08 2010-12-16 Takeda Pharmaceutical Company Limited Dihydropyrrolonaphtyridinone compounds as inhibitors of jak
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
WO2012085176A1 (en) * 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
DE102011008352A1 (de) 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
WO2012112567A1 (en) * 2011-02-15 2012-08-23 Georgetown University Small molecule inhibitors of agbl2
WO2013123444A1 (en) 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
WO2015146928A1 (ja) * 2014-03-24 2015-10-01 武田薬品工業株式会社 複素環化合物
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
JP7292394B2 (ja) * 2018-12-21 2023-06-16 サルティゴ・ゲーエムベーハー ２－アルコキシ－４－アミノ－５－メチル－ピリジン及び／又は２－アルコキシ－４－アルキルアミノ－５－メチル－ピリジンを調製するためのプロセス
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220202820A1 (en) 2019-04-16 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
EP4298099A1 (de) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclische lactame als jak2-v617f-inhibitoren
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
EP4526469A1 (de) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Verfahren zur beurteilung der erschöpfung von hämatopoetischen stammzellen durch chronische entzündung
WO2024026128A2 (en) * 2022-07-29 2024-02-01 Ensem Therapeutics, Inc. Tricyclic aryl derivatives, and compositions and methods thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1826859A (en) * 1928-03-15 1931-10-13 Emil C Anderson Corrugated metallic wall plate
US2008640A (en) * 1934-03-17 1935-07-16 Nat Steel Car Corp Ltd Reenforced corrugated car ends
US2218688A (en) * 1938-04-21 1940-10-22 John W Stewart Ship construction
US2585980A (en) * 1946-06-26 1952-02-19 Vasta John Ship construction
US2741208A (en) * 1951-08-24 1956-04-10 Albiach Vincent Tank ship bulkhead and girder construction
US3110523A (en) * 1960-10-28 1963-11-12 Int Harvester Co Emergency releasing means for vehicle brakes
DE1450432B2 (de) * 1963-06-27 1976-01-08 Technigaz S.A., Paris Abwickelbare Dehnungswand tür einen Behälter
DE1501738C3 (de) * 1965-03-15 1974-05-22 Mcmullen, John Joseph, Montclair, N.J. (V.St.A.) Wärmeisolierter doppelwandiger Tank zur Lagerung oder zum Transport tiefsiedender verflüssigter Gase bei etwa atmosphärischem Druck
FR1554714A (de) * 1967-10-12 1969-01-24
FR1568290A (de) * 1968-03-26 1969-05-23
GB1302214A (de) * 1970-03-19 1973-01-04 Conch Int Methane Ltd
GB1346771A (en) * 1970-05-20 1974-02-13 Hamilton W Low temperature cargo containers for ships
US3721362A (en) * 1970-09-09 1973-03-20 Mc Mullen J Ass Inc Double wall corrugated lng tank
US3811593A (en) * 1971-01-27 1974-05-21 Mc Millen J Ass Inc Double wall cargo tank having insulating secondary barrier
US3978808A (en) * 1973-09-11 1976-09-07 John J. Mcmullen Associates, Inc. Double wall cargo tank for transporting cryogenics
US3941272A (en) * 1974-03-27 1976-03-02 Kaiser Aluminum & Chemical Corporation Cryogenic transport
US4032608A (en) * 1974-07-12 1977-06-28 Kaiser Aluminum & Chemical Corporation Cryogenic liquid containment method
US3927788A (en) * 1974-07-12 1975-12-23 Kaiser Aluminium Chem Corp Cryogenic liquid containment system
US4116150A (en) * 1976-03-09 1978-09-26 Mcdonnell Douglas Corporation Cryogenic insulation system
US4207827A (en) * 1976-08-20 1980-06-17 Michel Gondouin System, tooling and method of construction of cryogenic tanks for LNG tankers and for LNG storage
US4101045A (en) * 1977-04-12 1978-07-18 Baltek Corporation Cryogenic container
DE3611920A1 (de) * 1986-04-09 1987-10-22 Vft Verkaufsges Teer Schiff fuer den fluessigtransport hochschmelzender aromatischer kohlenwasserstoffe
US5375547A (en) * 1993-04-09 1994-12-27 Ishikawajima-Harima Heavy Industries Co., Ltd. Self-standing liquefied gas storage tank and liquefied gas carrier ship therefor
TW242607B (de) * 1993-05-27 1995-03-11 Ishikawajima Harima Heavy Ind
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5727492A (en) * 1996-09-16 1998-03-17 Marinex International Inc. Liquefied natural gas tank and containment system
NO983204L (no) * 1998-04-16 1999-10-18 Allied Applied Marine Technolo Bulk carrier
US7111750B2 (en) * 1998-10-15 2006-09-26 Exxonmobil Upstream Research Company Liquefied natural gas storage tank
US6732881B1 (en) * 1998-10-15 2004-05-11 Mobil Oil Corporation Liquefied gas storage tank
ATE295365T1 (de) * 2000-02-09 2005-05-15 Novartis Pharma Gmbh Pyridinderivative als angiogenese- und/oder vegf- rezeptor-tyrosinkinase-inhibitoren
SI1303506T1 (en) * 2000-07-14 2005-06-30 Altana Pharma Ag 6-heteroarylphenanthridines
US6626319B2 (en) * 2001-06-04 2003-09-30 Electric Boat Corporation Integrated tank erection and support carriage for a semi-membrane LNG tank
EP1414443B1 (de) * 2001-08-01 2006-11-15 Merck & Co., Inc. BENZIMIDAZO 4,5-f|ISOCHINOLINON-DERIVATE
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
US20090258852A1 (en) * 2005-07-08 2009-10-15 Arrington Kenneth L Inhibitors of Checkpoint Kinases

Also Published As

Publication number Publication date
WO2008112217A1 (en) 2008-09-18
US20100160309A1 (en) 2010-06-24
EP2134346B1 (de) 2011-09-21
CA2679694A1 (en) 2008-09-18
JP2010521459A (ja) 2010-06-24
US8329722B2 (en) 2012-12-11
EP2134346A1 (de) 2009-12-23
EP2134346A4 (de) 2010-07-21
AU2008226844A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
ATE499364T1 (de) Hemmer der akt aktivität
WO2010011375A3 (en) Inhibitors of janus kinases
PH12016500531A1 (en) Compound inhibiting activities of btk and/or jak3 kinases
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
GEP20125368B (en) Kinase inhibitors
UA116768C2 (uk) Дизаміщені бензотієнілпіролотриазини та їх застосування як інгібіторів кінази рфрф
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
MY139689A (en) Imidazotriazines as protein kinase inhibitors
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2010005300A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus.
WO2006135604A3 (en) Inhibitors of checkpoint kinases
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
WO2007061764A3 (en) Tricyclic compounds useful as inhibitors of kinases
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MA31336B1 (fr) Inhibiteurs de pi3k alpha a base de pyridopyrimidinone
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties